Market Research Logo

Global Hemophilia Drugs Market 2016-2020

Global Hemophilia Drugs Market 2016-2020

About Hemophilia

Hemophilia is an X-linked genetic disorder that results in excessive blood loss during an injury, causing fatigue or even death. The disorder is more common in males and affects roughly 400,000 people globally every year. Hemophilia A is the more common form of this disorder, while hemophilia B is the rare form of hemophilia. To mitigate this disorder, plasma-derived clotting factors or recombinant clotting factors have been developed and are administered to the affected individual. The therapy is usually done in two ways: short acting therapeutic and long-acting therapeutic.

Technavio’s analysts forecast the global hemophilia drugs market to grow at a CAGR of 4.76% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global hemophilia drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of of drugs used for the treatment of hemophilia, including hemophilia A, hemophilia B, and inhibitors.The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Hemophilia Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Baxalta
  • Bayer
  • CSL Behring
  • Novo Nordisk
  • Pfizer
Other prominent vendors
  • Alnylam Pharmaceuticals
  • Amarna Therapeutics
  • Asklepios BioPharmaceutical
  • Biogen
  • BioMarin
  • Catalyst Bioscience
  • Chiesi Farmaceutici
  • Dimension Therapeutics
  • Emergent BioSolutions
  • F. Hoffmann-La Roche
  • Grifols, Kedrion Biopharma
  • Octapharma
  • rEVO Biologics
  • OPKO Biologics
  • Sangamo Biosciences
  • Spark Therapeutics
  • Swedish Orphan Biovitrum
  • UniQure Biopharma.
Market driver
  • Focus on prophylactic treatment
  • For a full, detailed list, view our report
Market challenge
  • Low diagnosis rate
  • For a full, detailed list, view our report
Market trend
  • Increase in technological innovations
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Hemophilia Drugs Market 2016-2020

Technavio recognizes the following companies as the key players in the global hemophilia drugs market: Baxalta, Bayer, CSL Behring, Novo Nordisk, and Pfizer.

Other Prominent Vendors in the market are: Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios BioPharmaceutical, Biogen, BioMarin, Catalyst Biosciences, Chiesi Farmaceutici, Dimension Therapeutics, Emergent BioSolutions, F. Hoffmann-La Roche, Grifols, Kedrion Biopharma, Octapharma, rEVO Biologics, OPKO Biologics, Sangamo Biosciences, Spark Therapeutics, Swedish Orphan Biovitrum, and UniQure Biopharma.

Commenting on the report, an analyst from Technavio’s team said: “One trend gaining traction in this market is increase in technological innovations. Currently, most of the hemophilia therapeutics available in the market are short-acting i.e., used only for when the individual suffers from bleeding. Apart from this, it is also observed that many of these products exhibit immunogenic reactions, which result in a reduced therapeutic effect of these products.”

According to the report, drugs with prolonged action will drive the market. Earlier, parenteral formulations for treating hemophilia B required frequent administration of replacement factors. Drugs with favorable pharmacokinetic profiles, including prolonged mechanism of action are fast gaining acceptance among physicians and individuals. These long-acting formulations reduce the need for repeated dosing of medications, reducing injection site pain. ALPROLIX by Biogen is one such drug.

Further, the report states that the diagnosis rates of hemophilia are very low, especially in the developing countries like China and India. In the developed regions such as Germany, Australia, and the US, the disease diagnosis rate is more than 80%. However, in developing countries such as China, India, and Indonesia, disease diagnosis rates are 56%, 12%, and 4%, respectively. The low diagnosis rate of hemophilia in developing countries is due to inadequate treatment facilities, limited disease knowledge, and a shortage of treatment supplies.



Companies Mentioned

Baxalta, Bayer, CSL Behring, Novo Nordisk, Pfizer, Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios BioPharmaceutical, Biogen, BioMarin, Catalyst Biosciences, Chiesi Farmaceutici, Dimension Therapeutics, Emergent BioSolutions, F. Hoffmann-La Roche, Grifols, Kedrion Biopharma, Octapharma, rEVO Biologics, OPKO Biologics, Sangamo Biosciences, Spark Therapeutics, Swedish Orphan Biovitrum, UniQure Biopharma.

  • Executive Summary
    • Highlights
  • Scope of the report
    • Market overview
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Process of gene therapy
      • Table Key buying criteria for global hemophilia drugs market 2015
      • Table Key customer segments of hemophilia drugs market
  • Pipeline portfolio
    • Table Pipeline portfolio: Global hemophilia drugs market
    • Table Pipeline share of major companies
  • Market landscape
    • Market overview
      • Table Global hemophilia drugs market snapshot: Developed and emerging markets 2015
    • Market size and forecast
      • Table Global hemophilia drugs market 2015-2020 ($ billions)
      • Table Impact of factors affecting the market 2015 and 2020
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by type of disease
    • Table Segmentation of global hemophilia drugs market by disease type based on revenue 2015
    • Table Global hemophilia drugs market segmentation growth lifecycle analysis
    • Table Global hemophilia drugs market by disease type 2015-2020
    • Global hemophilia A drugs market
      • Table Global hemophilia A drugs market 2015-2020 ($ billions)
    • Global hemophilia inhibitors treatment market
      • Table Global hemophilia inhibitors treatment market 2015-2020 ($ billions)
    • Global hemophilia B drugs market
      • Table Global hemophilia B drugs market 2015-2020 ($ billions)
    • Global von Willebrand disease treatment market
      • Table Global von Willebrand disease treatment market 2015-2020 ($ millions)
  • Market segmentation by type of therapy
    • Table Segmentation of global hemophilia drugs market by type of therapy based on revenue 2015
    • Table Global hemophilia drugs market by type of therapy 2015-2020
    • Recombinant therapies
      • Table Recombinant therapies in global hemophilia drugs market 2015-2020 ($ billions)
    • Plasma-derived therapies
      • Table Plasma-derived therapies in global hemophilia drugs market 2015-2020 ($ billions)
  • Market segmentation by type of disease management
    • Table Segmentation of hemophilia inhibitors treatment market by type of disease management based on revenue 2015
    • Prophylaxis
    • On-demand therapy
    • Inhibitor therapy
  • Geographical segmentation
    • Table Global hemophilia drugs market by geography 2015-2020
    • Table Percentage share of global hemophilia drugs market by geography 2015 and 2020
    • Table Global hemophilia drugs market segmentation by geography 2015-2020 ($ billions)
    • Table Global share of hemophilia drugs market by geography 2015
    • Table Global hemophilia drugs market segmentation by region: Market growth lifecycle analysis 2015
    • Table Global hemophilia drugs market: Country analysis based on revenue and growth rate
    • Hemophilia drugs market in Americas
      • Table Opportunity analysis of hemophilia drugs market in Americas
      • Table Hemophilia drugs market in Americas 2015-2020 ($ billions)
    • Hemophilia drugs market in EMEA
      • Table Opportunity analysis of hemophilia drugs market in EMEA
      • Table Hemophilia drugs market in EMEA 2015-2020 ($ billions)
    • Hemophilia drugs market in APAC
      • Table Opportunity analysis of hemophilia drugs market in APAC
      • Table Hemophilia drugs market in APAC 2015-2020 ($ billions)
  • Market drivers
    • Focus on prophylactic treatment
    • Drugs with prolonged action
    • Improved diagnostic procedures
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Low diagnosis rate
      • Table Percentage share of diagnosed and undiagnosed hemophilia population 2012-2016
    • High entry barriers
    • Cost-intensive complex treatment
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Increase in technological innovations
    • Development of gene therapy products
      • Table Gene therapies under development for hemophilia
    • Centralized buyers should pave the way to increased penetration
  • Vendor landscape
    • Competitive scenario
      • Table Market share of vendors 2015
      • Table Geographical presence of key vendors
      • Table Competitive scenario of global hemophilia drugs market vendors 2015-2020
    • Other prominent vendors
  • Key vendor analysis
    • Baxalta
      • Table Baxalta: Strength assessment
      • Table Baxalta: Strategy assessment
      • Table Baxalta: Opportunity assessment
      • Table Baxalta: YoY revenue and growth rates of hemophilia drugs 2013-2015 ($ billions)
    • Bayer
      • Table Bayer: Strength assessment
      • Table Bayer: Strategy assessment
      • Table Bayer: Opportunity assessment
      • Table Bayer: YoY revenue and growth rate of Kogenate FS 2013-2015 ($ billions)
    • CSL Behring
      • Table CSL Behring: Strength assessment
      • Table CSL Behring strategy assessment
      • Table CSL Behring opportunity assessment
      • Table CSL Behring: YoY revenue and growth rate of hemophilia drugs 2013-2015 ($ billions)
    • Novo Nordisk
      • Table Novo Nordisk: Strength assessment
      • Table Novo Nordisk: Strategy assessment
      • Table Novo Nordisk: Opportunity assessment
      • Table Novo Nordisk: YoY revenue and growth rates of hemophilia drugs 2013-2015 ($ billions)
    • Pfizer
      • Table Pfizer: Strength assessment
      • Table Pfizer: Strategy assessment
      • Table Pfizer: Opportunity assessment
      • Table Pfizer: Revenue of ReFacto AF/XYNTHA and BeneFIX 2015 ($ millions)
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report